Table 1.
Demographics; Cohort = 467total patients
| No dilation procedures (n=407) | Dilation procedure (n=60) | P value | |
|---|---|---|---|
|
| |||
| Gender, male, n (%) | 226(56) | 37 (62) | 0.37 |
|
| |||
| Race, n (%) | 0.09 | ||
| Caucasian | 361(89) | 54 (90) | |
| Black | 43 (11) | 4 (7) | |
| Other | 3 (0.01) | 2 (3) | |
|
| |||
| Native Lung Disease, n (%) | 0.19 | ||
| Obstructive | 167 (41) | 27 (45) | |
| Vascular | 11 (3) | 1 (2) | |
| Cystic | 78 (19) | 5 (8) | |
| Restrictive | 151(37) | 27 (45) | |
|
| |||
| Type of Transplant, bilateral, n (%) | 393 (97) | 59 (100) | 0.18 |
|
| |||
| Age at transplant, median (IQR) | 56 (43, 62) | 57 (50,62) | 0.14 |
|
| |||
| Ischemic time in minutes, median (IQR) | 366 (311, 445) | 389 (323, 432) | 0.56 |
|
| |||
| Length of stay posttransplant, median (IQR) | 13 (9, 23) | 18 (12, 32) | 0.003 |
|
| |||
| ECMO intraop and postop, n (%) | 17 (0.05) | 3 (0.05) | 1.00 |
|
| |||
| Tracheostomy posttransplant, n(%) | 28 (6.9) | 13 (22) | 0.0002 |
|
| |||
| Developed BOS (based on 428subjects eligible) | 150 (37) | 25 (46) | 0.72 |
|
| |||
| Number of PFTs, median (IQR) | 28 (20, 38) | 29 (19.5, 37.5) | 0.71 |
|
| |||
| Follow-up period, median days (IQR) | 1353 (748, 2190) | 1418 (822, 1717) | 0.28 |